Dawnzera is an RNA-targeted antisense oligonucleotide indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. It works by selectively reducing prekallikrein production, thereby lowering bradykinin formation, to significantly reduce the frequency and severity of swelling episodes. The drug is administered via a subcutaneous autoinjector every 4 weeks, offering a convenient self-injectable prophylactic option for this serious condition.